Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Zarnestra Phase III Data Needed Pre-Approval, Oncology Committee Says

May 05 2005

• By Andrew Kasper

Related Content

J&amp;J Zarnestra Efficacy Rate Likely To Be Focus Of Oncology Cmte. Review

May 04 2005

Additional Iressa Study Closed Due To Lack Of Survival Benefit

Apr 19 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window